No Data
ASCLETIS-B: Annual Report 2024
Hong Kong Stock Movement | ASCLETIS-B (01672) rose nearly 10% in the morning session as the research on obesity treatment drugs received positive top-line results and has submitted a Phase IIa research proposal to the FDA.
ASCLETIS-B (01672) rose nearly 10% in morning trading, as of the time of writing, it has increased by 5.13%, priced at 6.76 Hong Kong dollars, with a trading volume of 33.9117 million Hong Kong dollars.
Ascletis Pharma's Phase 1B Trial for Obesity Tablets Showed Favorable Safety Results
Hong Kong stocks fluctuated | CStone Pharmaceuticals (01672) rose more than 10% again, as ASC30 USA Phase Ib multi-dose incremental study achieved positive top-line results.
Singleron Pharmaceuticals (01672) increased by more than 10% again, as of the time of writing, up 4.39%, priced at 6.42 Hong Kong dollars, with a transaction volume of 26.8752 million Hong Kong dollars.
Express News | Ascletis Announces Positive Topline Results of U.S. Phase Ib Multiple Ascending Dose Study of Small Molecule Oral Glp-1R Agonist Asc30 and Submission of 13-Week Phase Iia Study Protocol to FDA
ASCLETIS-B (01672.HK): Small molecule oral GLP-1R agonist ASC30 has obtained positive top-line results in the multicenter phase Ib dose escalation study in the USA and has submitted the phase IIa study plan (13-week treatment course) to the FDA.
Gelonghui, April 23 - ASCLETIS-B (01672.HK) announced that its ASC30 oral tablet, administered once daily, has achieved positive top-line results in a randomized, double-blind, placebo-controlled phase Ib multiple ascending dose (MAD) study (NCT06680440) conducted in obese subjects in the USA (BMI: 30-40 kg/m2). This phase Ib MAD study includes three cohorts, each with a different weekly dose escalation scheme, a treatment period of 4 weeks, and a follow-up of 1 week. Scheme 1 (moderate starting dose, slow escalation: 2 mg, 5 mg, 10 mg, and 20 mg.
Anivid : over priced...